Eli Lilly (LLY) Q1 results:
Revenues: $5,859.8M (+15.1%).
Net Income: $1,456.5M (+159.6%); EPS: $1.60 (+180.7%); non-GAAP Net Income: $1,598.8M (+29.3%); non-GAAP EPS: $1.75 (+31.6%).
Key product sales: Trulicity: $1,229.4M (+40%);
Humalog: $695.8M (-5%); Alimta: $560.1M (+12%); Taltz: $443.5M (+76%);
Humulin: $315.7M (+6%); Basaglar: $303.7M (+21%); Forteo: $272.4M
(-13%); Jardiance: $267.5M (+31%); Cyramza: $239M (+21%); Cymbalta:
$210.4M (+28%); Verzenio: $188M (+72%); Olumiant: $139.7M (+70%).
2020 guidance: Revenue: $23.7B-24.2B (unch); EPS: $6.20-6.40 from $6.18-6.28; non-GAAP EPS: $6.70-6.90 from $6.70-6.80.
The increased customer buying patterns and patient
prescription trends associated with COVID-19 experienced in Q1 will
largely be reversed over the course of 2020.
Clinical trial enrollment in existing studies, as well as initiation of new clinical trials, will resume in H2.
The company’s newest mealtime insulin received
approval in both the European Union and Japan for the treatment of
adults with diabetes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.